The FDA issued an emergency use authorization for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
The FDA issued an emergency use authorization for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.
